retatrutide phase 2 nejm 2023 obesity trial jastreboff Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide Phase 2 NEJM Trial:

Jedn z najwikszych barier w dostpie do nowoczesnego leczenia otyoci w Polsce jest brak refundacji przez Narodowy Fundusz Zdrowia (NFZ)

have shown that compared with intravenous glucose, the increase of plasma insulin level after oral glucose was greater, and the high level of insulin was maintained for a longer time, which provided a basis for intestinal factors to stimulate insulin secretion (Elrick et al., 1964)

Aging rewires metabolism, immunity, and gene regulation across organs, steadily sapping strength, cognition, and resilience

Libido is a brain-driven process powered by dopamine signaling

Some are prescribed off-label by medical providers

However, this status can change, and athletes bear responsibility for substances in their body regardless of intent or knowledge